Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2003-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1538-7836.2003.00281.xPMID 12871321
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Roles of protease-activated receptors in a mouse model of endotoxemia.

  2006cited by this paper
• Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.

  2003cited by this paper
• Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study.

  2002cited by this paper
• Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  2002cited by this paper
• Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333

  2002cited by this paper
• Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor.

  2002cited by this paper
• Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo‐ controlled, 12‐week study in early postmenopausal women

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.

  2001cited by this paper
• Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.

  2001cited by this paper
• Structure and Biology of Tissue Factor Pathway Inhibitor

  2001cited by this paper
• TAFI Meets the Sticky Ends

  2001cited by this paper
• Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women.

  2001cited by this paper
• The Effects of Hormone Replacement Therapy (HRT) on Hemostatic Variables in Women with Previous Venous Thromboembolism – Results from a Randomized, Double-Blind, Clinical Trial

  2001cited by this paper
• Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin

  2001cited by this paper
• Thrombogenic potential of human coronary atherosclerotic plaques.

  2001cited by this paper
• Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.

  2000cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

  2000cited by this paper
• Differential Effects of Oral and Transdermal Estrogen Replacement Therapy on Endothelial Function in Postmenopausal Women

  2000cited by this paper
• Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis

  2000cited by this paper
• Long-term effect of 17beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC.

  2000cited by this paper
• A New T-287C Polymorphism in the 5’ Regulatory Region of the Tissue Factor Pathway Inhibitor Gene

  2000cited by this paper
• The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women.

  1999cited by this paper
• Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives

  1999cited by this paper
• Hormone replacement therapy, heart disease, and other considerations.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women

  1997cited by this paper
• Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.

  1997cited by this paper
• Tissue-factor antigen and activity in human coronary atherosclerotic plaques.

  1997cited by this paper
• Effects of hormone‐replacement therapy on fibrinolysis in postmenopausal women

  1997cited by this paper
• Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

  1997cited by this paper
• Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study.

  1995cited by this paper
• Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

  1995cited by this paper
• Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

  1995cited by this paper
• Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.

  1991cited by this paper
• Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels.

  1990cited by this paper

• Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation

  2026cites this paper
• Selective Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Attenuates Metastatic and Angiogenic Capabilities of Melanoma and Lung Carcinoma in vitro

  2023cites this paper
• Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism.

  2023cites this paper
• Gerinnungsstörungen der Frau

  2018cites this paper
• Sex differences in ischaemic stroke: potential cellular mechanisms.

  2017cites this paper
• Endothelium-Dependent Hemostatic Factors in Women with Previous Gestational

  2016cites this paper
• Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy

  2016cites this paper
• Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency?

  2015cites this paper
• Hormone therapy for preventing cardiovascular disease in post-menopausal women.

  2015cites this paper
• Genetic determinants of tissue factor pathway inhibitor plasma levels

  2015influential citation
• Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis.

  2015cites this paper
• Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis

  2015cites this paper
• endothelial cells in normal conditions and in response to androgen Novel protein ADTRP regulates TFPI expression and function in human

  2013cites this paper
• Effects of in vitro fertilization on thrombosis and haemostasis and the relationship between infertility and cardiovascular disease

  2013cites this paper
• The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity.

  2012cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen.

  2011cites this paper
• Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy

  2011influential citation
• Tissue Factor Pathway Inhibitor: A New Link Among Arterial Stiffness, Pulse Pressure, and Coagulation in Postmenopausal Women

  2011cites this paper
• Tissue Factor and Tissue Factor Pathway Inhibitor as Key Regulators of Global Hemostasis: Measurement of Their Levels in Coagulation Assays

  2010cites this paper
• Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

  2010cites this paper
• Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability.

  2009cites this paper
• Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis

  2008cites this paper
• A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.

  2007cites this paper
• Changes in Hemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Administration in a Crossover-Designed Study

  2007cites this paper
• Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

  2007cites this paper
• Hormone therapy and raloxifene reduce the coagulation inhibitor potential

  2007cites this paper
• Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.

  2007cites this paper
• Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?

  2006cites this paper
• Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women

  2006cites this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• Genetic influence on thrombotic risk markers in the elderly – a Danish twin study

  2006cites this paper
• Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured.

  2006cites this paper
• Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.

  2006cites this paper
• In reply [6]

  2006cites this paper
• Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat.

  2005cites this paper
• Different effects of low-dose transdermal and oral oestrogen therapy on procarboxypeptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: A randomised, placebo-controlled study

  2005cites this paper
• HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women

  2005cites this paper
• Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

  2005cites this paper
• The effects of short‐term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI‐1

  2005cites this paper
• Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

  2004influential citation
• Clinical and biochemical aspects of the haemostatic balance in relation to development and prevention of cardiovascular diseases

  2004cites this paper
• Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease

  2004cites this paper